logo

Exclusive Market Insight

& Scientific analysis

subscribe today
  • Exclusive Posts
  • Industry Newsletters
  • Clinical Trials
  • Possible Takeovers
  • Technology of the Week
  • Stock Table
  • Therapeutic Vaccines
  • Development-Stage Firms
  • Genomics
  • Prohost Picks
  • And much more...
Trick or TradeToday’s HighlightsProhost LettersNews & CommentsImpacting NewsContact
Login

Category: Today’s Highlights

Encouraging News from Cassava Sciences

Cassava Sciences Announces Top-Line Clinical Data for Simulfilam Cassava Sciences Press Release Today Cassava Sciences ( SAVA ) announced top-line clinical data today from a pre-planned interim analysis of an on-going open-label study with its drug candidate simufilam in patients...

Read More

September 22, 2021

0

The FDA Lifted the Clinical Hold on Solid Biosciences' IGNITE DMD Phase 1/2 Trial Sending the Stock Price Over 131%

Solid Biosciences Clinical Hold on IGNITE DMD is Lifted by the FDA Solid Biosciences ( SLDB ) - a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy, announced that the U.S. FDA has lifted the clinical...

Read More

October 1, 2020

0

AstraZeneca Saphnelo Approved in Japan for Adult Patients with SLE

AstraZeneca Saphnelo Approved by Japanese Ministry of Health, Labor and Welfare Developed by AstraZeneca ( AZN ) , Saphnelo is a first-in-class type I interferon receptor antibody shown to reduce overall disease activity in patients with systemic lupus erythematosus. The approval...

Read More

September 28, 2021

0

What Happened Over the Past Two Days and Biotech

Some Gains in Biotech Stocks During the War in Europe On Tuesday, Mar 8,2022 the United States’ government decided to ban the importation of Russian oil, liquefied natural gas and coal. This decision was made to further deprive Russia from...

Read More

March 10, 2022

0

Reata Pharmaceuticals Plans to Submit Omaveloxolone NDA for Friedreich’s Ataxia in Q1 2022

Reata Pharmaceuticals to Submit Omaveloxolone for NDA in Early 2022 In a press release following the completion of pre-NDA meeting with the FDA,  Reata Pharmaceuticals ( RETA ) stated that the purpose of the pre-NDA meeting was to discuss the...

Read More

September 30, 2021

0

Compugen Adds an Immuno-Oncology Pioneer to its Scientific Advisory Board. See Also: The New War Against Aging

Compugen New Addition, Dr. Nils Lonberg, PhD. Compugen ( CGEN ) announced the addition of Nils Lonberg, Ph.D., to its Scientific Advisory Board (SAB). Dr. Lonberg is a pioneer in the field of immuno-oncology and has more than 30 years...

Read More

October 8, 2020

0

Celldex Therapeutics Doses the First Patient with its CDX-0159 Product for Chronic Spontaneous Urticaria

Celldex Therapeutics After an expected resurrection, Celldex Therapeutics ( CLDX ) stock recovered and went as high as over $19 from less than $2 after an exaggerated selloff caused by  investors following the failure to treat the still untreatable glioblastoma...

Read More

October 13, 2020

0

Gilead Sciences: The FDA Approved Yescarta® - The First CAR T-Cell Therapy for Initial Treatment of Relapsed or Refractory LBCL

Gilead Sciences' Product Yescarta Kite - a Gilead Sciences ( GILD ) Company, announced the U.S. FDA has approved Yescarta® (axicabtagene ciloleucel) CAR T-cell therapy for adult patients with large B-cell lymphoma ( LBCL ) refractory to first-line chemo-immunotherapy or that which...

Read More

April 4, 2022

0

Intellia Therapeutics: Authorized to Initiate Phase 1/2 Clinical Trial of NTLA-2002 for Hereditary Angioedema

Intellia Therapeutics Authorization of CTA for Phase 1/2 Study of NTLA-2002 Intellia Therapeutics ( NTLA ) announced the authorization of its Clinical Trial Application ( CTA ) by the New Zealand Medicines and Medical Devices Safety Authority ( MEDSAFE ) to initiate...

Read More

October 6, 2021

0

Promising Agreement Between Jazz Pharmaceuticals and Werewolf Therapeutics

Jazz Pharmaceuticals and Werewolf Therapeutics Agreement Jazz Pharmaceuticals ( JAZZ ) and Werewolf Therapeutics ( HOWL ) entered into a licensing agreement under which Jazz has acquired exclusive global development and commercialization rights to Werewolf's investigational WTX-613, a differentiated, conditionally-activated interferon alpha...

Read More

April 8, 2022

0

  • Previous
  • 1
  • 2
  • ...
  • 125
  • 126
  • 127
  • ...
  • 172
  • 173
  • Next

Search ProhostBiotech

Popular Links

23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis 

September 19, 2024

0

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

0

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

0

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

0

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024

0

Prohost Biotech – Exclusive Biotech Research Copyright © 2026.
Privacy Policy